Valuation dashboard for ABVC BioPharma, Inc. (ABVC) with P/E N/A, P/B 3.18, EV/EBITDA -7.04 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer.
Analysis Summary
Trailing-twelve-month margins: gross margin 100.0%, operating margin 9.2%, net margin 9.9%.
At the current price of $1.08, ABVC has negative trailing earnings (P/E not meaningful) and an ROE of -71.17%. Market capitalisation stands at $28M.
Balance sheet quality for ABVC: current ratio of 0.4. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 3.18 |
| EV / EBITDA | -7.04 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ABVC | ABVC BioPharma, Inc. | $28M | 3.18 | -71.2% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $1.08 |
| Market Cap | $28M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -71.17% |
| Return on Invested Capital | -42.64% |
| Return on Assets | -37.55% |
| Gross Margin | 100.00% |
| Operating Margin | 918.55% |
| Net Margin | 992.85% |
Related companies: ATNM · FGEN · GRCE · JUNS · LTRN · LVTX · PDSB
Explore sector: Healthcare · Biotechnology
More sections of ABVC: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks